Trinity Capital Inc. Provides $20 Million in Growth Capital to Emboline, Inc. to Advance Interventional Heart Procedure Technology

Trinity Capital (Nasdaq: TRIN) committed $20 million in growth capital to Emboline to support commercial preparation for the Emboliner embolic protection catheter.

Rhea-AI Summary

Trinity Capital (Nasdaq: TRIN) committed $20 million in growth capital to Emboline to support commercial preparation for the Emboliner embolic protection catheter. The Emboliner uses a flexible mesh to capture and remove debris during minimally invasive heart procedures.

Emboline completed patient enrollment in the PROTECT H2H IDE clinical trial; funds will scale manufacturing, expand the team, and support clinical and regulatory milestones ahead of commercial launch.

Positive

• $20 million committed to fund commercial readiness and scaling
• Completed patient enrollment in the PROTECT H2H IDE trial

Negative

• Regulatory approval and commercial launch remain contingent on clinical data and IDE outcomes
• Commercial rollout dependent on successful manufacturing scale-up and milestone execution

Argus Mar 11 session

-0.60% close to close Open Argus

Details

News Market Reaction – TRIN

On Mar 11, the day this news came out, TRIN closed 0.60% below the previous close.

Data tracked by StockTitan Argus for the Mar 11 session.

Market Context

This announcement highlights Trinity Capital’s ongoing deployment of growth capital, committing $20M...

Analysis

This announcement highlights Trinity Capital’s ongoing deployment of growth capital, committing $20M to Emboline to support commercialization of its embolic protection technology for heart procedures. It follows recent sizeable financings and record 2025 results with higher investment income, NII, and AUM. Investors may focus on how this MedTech exposure complements existing portfolio sectors, the company’s ability to maintain low non-accrual levels, and upcoming financial updates to gauge the impact of new commitments.

Key Figures

Growth capital: $20 million Growth capital: $50 million Total investment income: $293.7M +5 more

Growth capital

$20 million

Growth capital commitment to Emboline, March 2026

Growth capital

$50 million

Growth capital commitment to Dwelly on Feb 26, 2026

Total investment income

$293.7M

2025 total investment income, +23.5% YoY

NII per share

$2.08 per share

2025 net investment income per share

NAV per share

$13.42

NAV per share at year-end 2025

Platform AUM

$2.8B

Platform assets under management at year-end 2025

Gross investments funded

$1.5B

Total gross investments funded in 2025, +21.3% YoY

Non-accruals (FV)

0.7%

Non-accrual investments as % of debt at fair value, Dec 31 2025

Historical Context

5 past events · Latest: Feb 26

5 events

1. Feb 26

   Growth capital deal

   24h Move

   -1.3%

   Committed $50M in growth capital to Dwelly for UK expansion.

2. Feb 25

   Earnings results

   24h Move

   +2.5%

   Reported record 2025 investment income, NII, NAV, and AUM growth.

3. Feb 03

   Earnings preview

   24h Move

   +0.5%

   Released preliminary Q4 and 2025 estimates for NII and NAV with low non-accruals.

4. Feb 02

   Growth capital deal

   24h Move

   -2.9%

   Committed £25M of growth capital to Motorway to support UK growth.

5. Jan 28

   Credit rating update

   24h Move

   +0.5%

   Morningstar DBRS confirmed investment grade rating at BBB (low) with Positive trend.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

emboliner embolic protection catheter, minimally invasive heart procedures, investigational device exemption (ide), clinical trial, +1 more

5 terms

emboliner embolic protection catheter medical

"Emboline's proprietary Emboliner® Embolic Protection Catheter is designed"

A embolic protection catheter is a small, flexible medical tube used during heart or blood vessel procedures to catch and remove debris that can break free and travel to the brain or other organs; think of it as a tiny filter or sieve placed downstream during surgery. For investors, its use can reduce complication rates, influence adoption by hospitals, and affect regulatory clearance, reimbursement and market demand for companies that make or sell such devices.

minimally invasive heart procedures medical

"make minimally invasive heart procedures safer by capturing and removing"

Minimally invasive heart procedures are medical treatments performed through small cuts or by threading thin tubes and instruments to the heart, avoiding large open‑chest surgery. For investors, they matter because they tend to lower hospital time and recovery costs, expand the number of patients who can be treated, and drive demand for specialized devices, tools and services—factors that influence healthcare revenue, regulatory risk and long‑term growth.

investigational device exemption (ide) regulatory

"the PROTECT H2H investigational device exemption (IDE) clinical trial"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device to be used in clinical studies so companies can gather safety and effectiveness data before full market approval. For investors, an IDE is a key milestone because it lets a company test real-world performance and move toward commercial clearance or approval—much like a trial run that, if successful, can unlock larger revenue opportunities and reduce regulatory risk.

clinical trial medical

"completed patient enrollment in the PROTECT H2H investigational device"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

regulatory approval regulatory

"data needed for regulatory approval and the commercial launch of the"

Regulatory approval is the official permission given by government agencies or authorities that allows a product, service, or business activity to be legally operated or sold. It is important to investors because receiving approval often indicates that a product has been reviewed for safety and compliance, which can influence its success and the company’s prospects in the market. Without this approval, launching or selling certain products may be restricted or prohibited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHOENIX, March 11, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) ("Trinity"), a leading international alternative asset manager, today announced the commitment of $20 million in growth capital to Emboline, Inc. ("Emboline"), a MedTech company focused on reducing strokes and other complications during interventional heart procedures.

Emboline's proprietary Emboliner^® Embolic Protection Catheter is designed to help make minimally invasive heart procedures safer by capturing and removing debris that could otherwise reach the brain and other vital organs. The Emboliner is composed of a flexible, conforming mesh that allows normal blood flow while providing protection during procedures. The company recently completed patient enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, advancing its efforts to generate the clinical data needed for regulatory approval and the commercial launch of the Emboliner system.

 "We're proud to partner with the Emboline team as they advance their mission to reduce strokes and other complications associated with heart procedures," said Rob Lake, Senior Managing Director at Trinity Capital. "The team's passion and dedication to improving patient safety is inspiring, and we're excited to support them as they expand access to the Emboline system."

"We are entering an important phase as we prepare for the commercial introduction of the Emboliner system," said Scott Russell, President and CEO of Emboline. "Trinity Capital's growth financing strengthens our ability to scale manufacturing, expand our team, and support the clinical and regulatory milestones that will bring this technology to patients worldwide."

This financing will support Emboline in preparing for the commercial launch of the Emboliner system while continuing to advance its platform of technologies aimed at reducing risk during minimally invasive heart procedures.

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

About Emboline
Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, focused on developing technologies designed to reduce embolic complications during transcatheter cardiovascular procedures. The company's lead product, the Emboliner^® Embolic Protection Catheter, is designed to provide full cerebral and systemic embolic protection by capturing and removing debris that may be released during structural heart interventions and that could otherwise travel to the brain and other vital organs.
For more information, visit emboline.com.
The Emboliner^® device is currently investigational and is not available for commercial sale.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-20-million-in-growth-capital-to-emboline-inc-to-advance-interventional-heart-procedure-technology-302710135.html

SOURCE Trinity Capital Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Trinity Capital (TRIN) announce about funding for Emboline on March 11, 2026?

Trinity Capital committed $20 million in growth capital to Emboline. According to Trinity Capital, the financing will support commercialization preparations, manufacturing scale-up, team expansion, and clinical and regulatory milestones.

What is the Emboliner device that Emboline will commercialize with TRIN funding?

The Emboliner is an embolic protection catheter with a flexible, conforming mesh designed to capture and remove debris. According to Emboline, it allows normal blood flow while protecting against debris during heart procedures.

What clinical progress did Emboline report related to the Emboliner on March 11, 2026?

Emboline completed patient enrollment in the PROTECT H2H IDE clinical trial. According to Emboline, the enrollment advances generation of clinical data needed for regulatory approval and commercial launch.

How will the $20 million from TRIN be used by Emboline?

The financing will fund manufacturing scale-up, team expansion, and support clinical and regulatory milestones. According to Emboline, these uses aim to prepare the Emboliner system for commercial introduction.

Does the TRIN investment mean the Emboliner is commercially approved?

No, commercial approval is not yet confirmed; it remains subject to trial results and regulatory review. According to Emboline, the PROTECT H2H IDE trial data are needed to pursue regulatory approval and launch.